Literature DB >> 27233598

Analytical performance of nano-LC-SRM using nondepleted human plasma over an 18-month period.

Xiaomin Song1, Ardeshir Amirkhani1, Jemma X Wu1, Dana Pascovici1, Thiri Zaw1, Dylan Xavier1, Stephen J Clarke2, Mark P Molloy1.   

Abstract

A standardized procedure for label-free nano-LC-SRM analysis of 32 high-medium abundance proteins from nondepleted human plasma was established and SRM data were acquired on 45 separate days for a control sample that was independently prepared on 39 distinct dates over an 18-month period (542 days). This case study enabled us to assess quantitative variance associated with nano-LC-SRM plasma analysis, mimicking experimental conditions that would be experienced with clinical trial biomarker studies. We assessed sample preparation variability attributed to different technicians and sample storage stability. Instrument performance varied over the 18-month period requiring ion path cleaning, so we assessed the impact of declining performance on specific peptide ion sensitivity and evaluated how various data normalization strategies could compensate for these changes. Our analysis demonstrated that while sample preparation was the main contributor for data variances when MS data were acquired within days, variability in SRM sensitivity was a far greater source of variance when data were acquired over a long period. The overall median multiplexed assay CV was 13% over the 18-month period. This case study is illustrative of large-scale plasma biomarker studies using nano-LC-SRM over extended periods and highlights aspects of bioanalysis that require careful attention to ensure reliable quantitation.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Biomarker; Mass spectrometry; Plasma; Quantitation; Selected reaction monitoring; Technology

Mesh:

Substances:

Year:  2016        PMID: 27233598     DOI: 10.1002/pmic.201500507

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  2 in total

1.  Obesity shows preserved plasma proteome in large independent clinical cohorts.

Authors:  Ornella Cominetti; Antonio Núñez Galindo; John Corthésy; Armand Valsesia; Irina Irincheeva; Martin Kussmann; Wim H M Saris; Arne Astrup; Ruth McPherson; Mary-Ellen Harper; Robert Dent; Jörg Hager; Loïc Dayon
Journal:  Sci Rep       Date:  2018-11-19       Impact factor: 4.379

2.  The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT].

Authors:  Stephen John Clarke; Matthew Burge; Kynan Feeney; Peter Gibbs; Kristian Jones; Gavin Marx; Mark P Molloy; Timothy Price; William H H Reece; Eva Segelov; Niall C Tebbutt
Journal:  PLoS One       Date:  2020-03-06       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.